pixabay
–
Vaccines for children 12 to 17 years of age are safe.
–
Nextren.com – The Sionvac vaccine made in China has been used in many countries, and provides good effectiveness among adults and the elderly.
In addition to adults and the elderly, vaccine targets in several countries including Indonesia are starting to be directed at children under 17 years old, and their feasibility is being researched.
In China, Sinovac’s COVID-19 vaccine has been approved for emergency use among the population aged between 3 and 17 years.
The policy comes after data from a phase-II clinical trial showed it was at least 98.9 percent effective in producing antibodies in children ages 3 to 17.
Also Read: Viral Film The Penthouse Becomes Vaccine Bond, Turns out this is the Voice Dubbing Process
This is a higher efficacy rate than in the population over 18 years old, as reported by China’s Global Times.
The experiment involved 180 volunteers in that age group.
Three months after vaccination, antibody production among the population aged 3 to 17 was 98.9 to 100 percent depending on the inoculated dose, the company announced on Monday.
The results were better than in the population over the age of 18, Sinovac said, noting that the data showed the vaccine was stable and effective among young people.
WHO in June validated the Sinovac COVID-19 vaccine for emergency use in people 18 years of age and older.
The efficacy results showed that the Sinovac vaccine prevented symptomatic disease in 51 percent of those vaccinated.
This means that the vaccine could prevent severe COVID-19 and hospitalization in 100 percent of the population studied.
Also Read: Sophisticated! Bio Farma Prepares a Covid-19 Vaccine Tracking Application!
Sinovac was approved for emergency use in May for people between 3 and 17 years of age.
Several provinces and cities in China have inoculated 15- to 17-year-olds since July and plan to expand inoculation to more people, the company said.
PROMOTED CONTENT
Featured Videos
– .
